MeiraGTx has announced positive data from a small Parkinson's disease trial involving AAV-GAD gene therapy, while a phase II study highlights the potential of CVN424, a GPR6 inverse agonist, in managing "off" time in Parkinson's patients. These findings offer new avenues for treatment in a disease with significant unmet needs.
AAV-GAD Gene Therapy Shows Promise
The investigational gene therapy AAV-GAD, which delivers the glutamic acid decarboxylase (GAD) gene to the subthalamic nucleus, aims to increase GABA levels in the brain. In a recent trial, a high dose of AAV-GAD was found to be safe, well-tolerated, and demonstrated an improvement in motor scores among Parkinson's disease patients. The therapy targets the underlying neurochemical imbalances associated with the disease by enhancing GABAergic neurotransmission.
CVN424 Reduces "Off" Time in Phase II Study
CVN424, a GPR6 inverse agonist, has also shown potential in treating Parkinson's disease. A phase II study revealed that CVN424 at a dose of 150 mg/day led to a clinically meaningful reduction in daily "off" time. The drug was reported to be safe and well-tolerated. These "off" periods, characterized by motor fluctuations and non-motor symptoms, significantly impact the quality of life for individuals with Parkinson's disease. The GPR6 target represents a novel approach to managing these debilitating fluctuations.
MIND Diet and Cognitive Decline
In related research, the MIND diet was associated with slower cognitive decline in both Black and white older adults. However, the relationships appeared to vary with other lifestyle and vascular factors, according to a study published in Alzheimer's and Dementia.
Multiple Sclerosis Fatigue
The COMBO-MS trial, published in Lancet Neurology, indicated that modafinil (Provigil), cognitive behavioral therapy, and a combination of both were associated with similar reductions in the effects of multiple sclerosis (MS) fatigue at 12 weeks.
